Advertisement

Gastric Cancer

  • Jennifer S. Chang
  • Mekhail Anwar
  • Hans T. Chung
Chapter
First Online:

Abstract

This chapter will discuss the epidemiology, workup, treatment, and follow-up for gastric cancer.

Keywords

Gastric cancer 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

We thank Charlotte Dai Kubicky MD, PhD, and Jennifer S. Yu, MD, for their work on the prior edition of this chapter.

References

  1. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.CrossRefPubMedGoogle Scholar
  2. Al-Batran S-E, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxalipatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15_suppl):4004.Google Scholar
  3. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379:315–21.CrossRefPubMedGoogle Scholar
  4. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999 Mar 25;340(12):908–14.CrossRefPubMedGoogle Scholar
  5. Cunningham D, Alum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMedGoogle Scholar
  6. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30:303–8.CrossRefPubMedGoogle Scholar
  8. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. J Clin Oncol. 2011. ASCO Annual Meeting Abstracts Part 1;29:4003.CrossRefGoogle Scholar
  9. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMedGoogle Scholar
  10. Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim result from an international, intergroup trial of the AGITG, TROG, EORT and CCTG. Ann Surg Oncol. 2017;24(8):2252–8.Google Scholar
  11. Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomized phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMedGoogle Scholar
  13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: gastric cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf. Accessed 15 Jan 2017.
  14. Park SH, Son TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33:3130–6.CrossRefPubMedGoogle Scholar
  15. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan clinical oncology group study 9501. J Clin Oncol. 2004;22:2767–73.CrossRefPubMedGoogle Scholar
  16. Sasako M, Sano T, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer – JCOG 9501. N Engl J Med. 2008;359:453–62.CrossRefPubMedGoogle Scholar
  17. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2009;28(35):5210–8.CrossRefGoogle Scholar
  18. Schwartz GK, Winter K, Minsky BD, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG- 0114). J Clin Oncol. 2009;27(12):1956–62.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric resection. J Clin Oncol. 2012;31(19):2327–33.CrossRefGoogle Scholar
  20. Songun I, Putter H, Kranenbarg EM-K, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMedGoogle Scholar
  21. Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12:187–95.CrossRefPubMedGoogle Scholar
  22. Verheij M, Cats A, Jansen EPM, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study. ESMO World Congress on Gastrointestinal Cancer. Abstract LBA-02. Presented June 30, 2016.Google Scholar
  23. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006 Apr;7(4):309–15.CrossRefPubMedGoogle Scholar
  24. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jennifer S. Chang
    • 1
  • Mekhail Anwar
    • 2
  • Hans T. Chung
    • 3
  1. 1.Department of Radiation Oncology, University of California San FranciscoMarin General HospitalSan FranciscoUSA
  2. 2.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of Radiation Oncology, Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada

Personalised recommendations

Cite chapter